Analysts Set Hologic, Inc. (NASDAQ:HOLX) Target Price at $85.55

Shares of Hologic, Inc. (NASDAQ:HOLX) have earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $87.60.

A number of research analysts have weighed in on HOLX shares. Royal Bank of Canada raised their price objective on shares of Hologic from $81.00 to $82.00 and gave the company a “sector perform” rating in a research note on Tuesday. JPMorgan Chase & Co. lifted their price target on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research note on Tuesday. Argus increased their price objective on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Evercore ISI lifted their target price on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday. Finally, Stephens reiterated an “overweight” rating and set a $92.00 price target on shares of Hologic in a report on Tuesday.

Hologic Stock Performance

Shares of Hologic stock opened at $81.61 on Thursday. The business has a 50-day simple moving average of $74.95 and a 200 day simple moving average of $75.19. Hologic has a one year low of $64.02 and a one year high of $82.65. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.99 and a quick ratio of 3.29. The firm has a market capitalization of $19.05 billion, a price-to-earnings ratio of 41.64, a PEG ratio of 2.75 and a beta of 0.99.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 EPS for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter in the previous year, the company posted $0.93 earnings per share. The company’s quarterly revenue was up 2.7% on a year-over-year basis. On average, research analysts anticipate that Hologic will post 4.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Hologic news, insider Stephen P. Macmillan 44,039 shares of Hologic stock in a transaction that occurred on Tuesday, July 30th. The was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other Hologic news, CEO Stephen P. Macmillan sold 3,672 shares of the business’s stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares in the company, valued at $92,755,443.06. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Stephen P. Macmillan 44,039 shares of the company’s stock in a transaction dated Tuesday, July 30th. The disclosure for this trade can be found here. 1.75% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hologic

Institutional investors have recently added to or reduced their stakes in the business. Massmutual Trust Co. FSB ADV raised its position in shares of Hologic by 24.7% in the first quarter. Massmutual Trust Co. FSB ADV now owns 691 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 137 shares during the period. Graypoint LLC grew its stake in Hologic by 3.9% in the 1st quarter. Graypoint LLC now owns 3,871 shares of the medical equipment provider’s stock valued at $302,000 after buying an additional 147 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in Hologic by 2.3% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 7,215 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 165 shares during the period. Arizona State Retirement System lifted its position in shares of Hologic by 0.3% during the fourth quarter. Arizona State Retirement System now owns 67,319 shares of the medical equipment provider’s stock worth $4,810,000 after acquiring an additional 172 shares in the last quarter. Finally, Lincoln National Corp boosted its holdings in shares of Hologic by 4.0% in the fourth quarter. Lincoln National Corp now owns 4,675 shares of the medical equipment provider’s stock worth $334,000 after acquiring an additional 178 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.